CoChat
Sign Up
Cited by 25Pituitary Gland Disorders and TreatmentsNeuroendocrine Tumor Research AdvancesAdrenal and Paraganglionic Tumors

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors

Open access
Tani, Yuji, Sugiyama, Toru, Izumiyama, Hajime, Yoshimoto, Takanobu, Yamada, Shozo, Hirata, Yukio·2011·Endocrine Journal
DOI 10.1507/endocrj.k10e-389
Open this paper in CoChat — free accountOpen PDF

Abstract

The differential gene expression of proopiomelanocortin (POMC)-related processing enzymes, transcription factors, and receptors responsible for ACTH secretion between non-pituitary and pituitary ACTH-secreting tumors remains obscure. This study was attempted to determine the gene expression profiles of transcription factors (Tpit, NeuroD1 and IKZF1), proprotein convertase (PC) 1/3 and PC2, and several key receptors linked to ACTH secretion, including corticotrophin releasing hormone receptor (CRHR1), vasopressin receptor 1b (V1bR), somatostatin receptor (SSTR) subtype-2, -5 and dopamine receptor type 2 (D2R) in non-pituitary and pituitary ACTH-secreting tumors. Surgical tissue specimens from carcinoid tumors causing ectopic ACTH syndrome (EAS: n=4) and pituitary tumors causing Cushing's disease (CD: n=13), were subjected to real-time RT-PCR for measurements of each mRNA levels. POMC and CRHR1 mRNA levels in CD were far greater than those in EAS, whereas IKZF1, PC2, SSTR-2 and -5 mRNA levels in EAS were significantly greater than those in CD. NeuroD1, Tpit, PC1/3, V1bR and D2R mRNA levels were comparable between EAS and CD. In conclusion, differential gene expression profiles revealed more abundant mRNA expression in EAS than in CD of 1) IKZF1 with its potential implication of cell differentiation and hormone secretion, 2) PC2 with its possible enhanced processing activity of mature ACTH, and 3) SSTR-2 and -5 with their potential therapeutic application of more selective agonists in EAS patients.

Overview

Integrity signals

Registry

Crossref · 10.1507/endocrj.k10e-389

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most but not all patients with Cushing disease will have an increase in plasma ACTH by more than 50% and cortisol concentrations by more than 20% after CRH stimulation.

    “Therefore, most but not all patients with Cushing disease will have an increase in plasma ACTH by more than 50% and cortisol concentrations by more than 20% after CRH stimulation.”

    From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [82]

  • Patients with EAS are typically unresponsive to CRH, although some tumors, in particular bronchial carcinoids, can express CRH receptors.

    “Patients with EAS are typically unresponsive although some tumors, in particular bronchial carcinoids can express CRH receptors (9, 74, 81, 82).”

    From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [82]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. 10.1210/jc.80.1.294 · DOI
  2. 10.1210/jc.77.5.1308 · DOI
  3. 10.1210/jc.87.4.1640 · DOI

Cited by

Sorted by citations

Related

Metadata

Authors
Tani, Y., Sugiyama, T., Izumiyama, H., Yoshimoto, T., Yamada, S., & Hirata, Y.
Affiliations
  • Tokyo Medical and Dental University (JP)
  • Toranomon Hospital (JP)
ORCID
Venue
Endocrine Journal
Publisher
Japan Endocrine Society
Published
2011
Volume
58
Issue
4
Pages
297-303
ISSN
  • 0918-8959 (ISSN-L)
  • 1348-4540
DOI
10.1507/endocrj.k10e-389
OpenAlex
W2030802344
Cited by
25
References
35
Citations by year
2023: 1 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 3 · 2013: 1
FWCI
0.26
Type
journal article
Language
en
Open access
Locations
  • Endocrine Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Health, Labour and Welfare
  • Tokyo Medical and Dental University
  • Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
ACTH-secreting tumor, ectopic ACTH syndrome, Cushing's disease, proopiomelanocortin, IKZF1, NeuroD1, TPIT, CRHR1, somatostatin receptor 2, somatostatin receptor 5, dopamine D2 receptor, gene expression profiling, pituitary tumors, carcinoid tumor
MeSH terms
ACTH Syndrome, Ectopic, Adult, Aged, Female, Humans, Pituitary Neoplasms, Pro-Opiomelanocortin, RNA, Messenger, Transcription Factors, Receptors, Somatostatin, Receptors, Vasopressin, Receptors, Corticotropin-Releasing Hormone, Gene Expression Profiling, Proprotein Convertase 2, Pituitary ACTH Hypersecretion, Ikaros Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review